IGF1 and diabetic kidney disease: Inhibition of the IGF signalling pathway can inhibit TECS6 ribosomal protein hyperphosphorylation and block activation of the mTOR pathway without affecting mitochondrial structural defects, reducing kidney disease and providing a new target for the treatment of DKD.